Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Craig, Zimmerman"'
Autor:
Srdan, Verstovsek, Norio, Komatsu, Harinder, Gill, Jie, Jin, Sung-Eun, Lee, Hsin-An, Hou, Toshiaki, Sato, Albert, Qin, Raymond, Urbanski, Weichung, Shih, Oleh, Zagrijtschuk, Craig, Zimmerman, Ruben A, Mesa
Publikováno v:
Future Oncology. 18:2999-3009
Patients diagnosed with high-risk essential thrombocythemia (ET) have limited treatment options to reduce the risk of thrombosis and lessen the progression of the disease by targeting the molecular source. Hydroxyurea is the recommended treatment, bu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7149e0f2130e9f784334c81f228988f3
https://doi.org/10.2217/fon-2022-0596
https://doi.org/10.2217/fon-2022-0596
Autor:
Ruben Mesa, Norio Komatsu, Harinder Gill, Jie Jin, Sung-Eun Lee, Hsin-An Hou, Toshiaki Sato, Albert Qin, Raymond Urbanski, Weichung Shih, Oleh Zagrijtschuk, Craig Zimmerman, Srdan Verstovsek
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22
Low-dose aspirin with hydroxyurea (HU) is first-line therapy in high-risk essential thrombocythemia (ET). However, many patients become HU-intolerant or -resistant. Anagrelide (ANA) and peginterferon alfa-2a are second-line options for high-risk ET p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e69f8535ea993b4c55d3cabe134c013e
https://pubmed.ncbi.nlm.nih.gov/36164019
https://pubmed.ncbi.nlm.nih.gov/36164019
Publikováno v:
Blood. 140:6748-6749
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44dc0ffc3dd25ef2b71d42e127bede24
https://doi.org/10.1182/blood-2022-162693
https://doi.org/10.1182/blood-2022-162693
Autor:
Srdan, Verstovsek, Ruben, Mesa, John, Mascarenhas, Tsewang, Tashi, Weichung, Shih, Toshiaki, Sato, Raymond, Urbanski, Oleh, Zagrijtschuk, Craig, Zimmerman
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S342-S343
There is an unmet need for treatment options for patients with essential thrombocythemia (ET) who require cytoreduction who may or may not have been treated with hydroxyurea (HU) or anagrelide (ANA), which is commonly used outside of North America. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7873da0d0ce0233d78d75dbc545b3ea1
https://doi.org/10.1016/s2152-2650(22)01469-0
https://doi.org/10.1016/s2152-2650(22)01469-0
Autor:
Ruben Mesa, Norio Komatsu, Harinder Gill, Jie Jin, Sung-Eun Lee, Hsin-An Hou, Toshiaki Sato, Albert Qin, Raymond Urbanski, Weichung Shih, Oleh Zagrijtschuk, Craig Zimmerman, Srdan Verstovsek
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S160
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25f2f2a2c96e4c63f26575ecf77ff0db
https://doi.org/10.1016/s2152-2650(22)00983-1
https://doi.org/10.1016/s2152-2650(22)00983-1
Autor:
Srdan Verstovsek, Ruben Mesa, John Mascarenhas, Tsewang Tashi, Weichung Shih, Toshiaki Sato, Raymond Urbanski, Oleh Zagrijtschuk, Craig Zimmerman
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S160
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27d45d28f7b35a7c70ddd72a5ce331e0
https://doi.org/10.1016/s2152-2650(22)00984-3
https://doi.org/10.1016/s2152-2650(22)00984-3
Autor:
Albert Qin, Hsin-An Hou, Jie Jin, Ruben A. Mesa, Harinder Gill, Weichung Shih, Craig Zimmerman, Raymond Urbanski, Srdan Verstovsek, Oleh Zagrijtschuk, Toshiaki Sato, Norio Komatsu, Sung-Eun Lee
Publikováno v:
Blood. 138:1491-1491
Background: Essential thrombocythemia (ET) is a subtype of chronic myeloproliferative neoplasms (MPN) characterized by thrombocytosis and disease-related symptoms, which may be difficult to manage. Patients with ET are also at higher risk of thrombos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ecc87cfb71ae4960029f9310c0afd7fc
https://doi.org/10.1182/blood-2021-147417
https://doi.org/10.1182/blood-2021-147417
Autor:
Ruben A. Mesa, Amylou C. Dueck, Jeanne Palmer, John K. Camoriano, Craig Zimmerman, Heidi E. Kosiorek
Publikováno v:
Blood. 136:23-23
Background: Myelofibrosis (MF) is a clonal bone marrow disorder characterized by a constitutional symptoms, splenomegaly, anemia, elevated WBC and bone marrow fibrosis. Ruxolitinib is a JAK2 inhibitor approved for patients with Intermediate-2 (INT-2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25a8fed32903306b091892763bdf1d8f
https://doi.org/10.1182/blood-2020-138934
https://doi.org/10.1182/blood-2020-138934
Autor:
Craig Zimmerman
Boronizing is a case hardening process for metals to improve the wear life and galling resistance of metal surfaces. Boronizing can be carried out using several techniques. This article discusses the powder pack cementation process for carrying out b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfcbfff134038c8db3e7335e8a2b4156
https://doi.org/10.31399/asm.hb.v18.a0006420
https://doi.org/10.31399/asm.hb.v18.a0006420
Autor:
Lih Lisa Kang, Srdan Verstovsek, Zhijian Xiao, Oleh Zagrijtschuk, Chih-Cheng Chen, Chungwei Lee, Weichung Shih, Craig Zimmerman, Albert Qin, Hsin-An Hou, Norio Komatsu, Ruben A. Mesa
Publikováno v:
Journal of Clinical Oncology. 37:7055-7055
7055 Background: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN), covering broad spectrum of clinical scenarios, from asymptomatic patients with only isolated high platelets to highly morbid patients in late stage diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::878b4eff61a4e92e7a99ed3c90653474
https://doi.org/10.1200/jco.2019.37.15_suppl.7055
https://doi.org/10.1200/jco.2019.37.15_suppl.7055